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ABSTRACT: Developing clinically relevant synthetic agents that are capable of disrupting 
protein-protein interactions (PPIs) is now a major goal of scientific research. In an effort to explore 
new methodologies that are applicable to the design of synthetic PPI inhibitors, we examined a 
strategy based on the assembly of small module compounds to create multivalent mid-sized agents. 
This personal account describes three particular approaches based on module assembly: 
metal-chelating-based ligand assembly, covalent chemical ligation templated by a targeted protein, and 
bivalent inhibitor design for simultaneous targeting of the active pocket and protein surface. These 
strategies were shown to be useful for synthesizing minimally sized synthetic agents for targeting PPIs 
and may enable development of agents that are applicable to inhibition of intracellular PPIs.  
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Introduction 
Protein-protein interactions (PPIs) play a critical role in regulating signaling pathways in living 
systems, and dysregulation of PPIs is the mechanism of a large number of diseases.1 The number of 
PPIs in humans is estimated to be approximately 650,000,2 representing a substantial number of new 
clinical targets for development of therapeutic agents. Despite their therapeutic relevance and 
abundance, however, PPIs have not traditionally been considered as targets by the pharmaceutical 
industries due to the large and featureless nature of protein-protein interfaces, which precludes the 
effective binding and action of low-molecular-weight compounds. However, tremendous insights 
regarding PPIs have emerged from recent interdisciplinary research efforts and are now shedding light 
on many possible strategies and technologies to address the large interfaces implicated in PPIs. For 
example, the discovery that most of the binding energy of protein complexes is contributed by only 
subsets of amino acid residues3 has prompted researchers to search for synthetic molecules that bind to 
such “hotspots”. 1a In addition, recent biophysical studies revealed that protein interfaces are dynamic 
and can be flexible in solution,4 thus highlighting opportunities for identifying allosteric inhibitors.5 
These advances in the understanding of PPI mechanisms have led many pharmaceutical companies to 
focus their interests on protein interfaces as potential drug targets.6 Nonetheless, developing drug-like 
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small inhibitors of PPIs remains challenging. In fact, only a few small PPI inhibitors (molecular 
weight [MW] <500 Da) have been developed to date.  
We are interested in a group of molecules ranging in MW between roughly 600 and 2,000 Da as 
potential scaffolds for the development of PPI-directed agents. Although these relatively large 
molecules have been disregarded recently by pharmaceutical companies because many of them do not 
conform to Lipinski’s rule of five for drug-likeliness, we expected that their large molecular surface 
would allow for the introduction of multivalency and structural diversity, characteristics that are 
necessary for protein surface recognition. Recent examples, including the antitumor drug Eribulin 
(MW 730 Da), the Bcl-2 (B-cell lymphoma 2) inhibitor ABT-263 (MW 975 Da), and the integrin 
antagonist SAR1118 (MW 637 Da), have highlighted the potential applications of mid-sized 
molecules in therapeutics.7 Furthermore, promising new technologies for generating chemical libraries 
of macrocyclic peptides8 and heterocycles7 have recently been developed, and these libraries would 
allow for easier access to potential lead compounds of PPI inhibitors. This personal account describes 
our recent efforts focused on the development of a new methodology for PPI-directed agents based on 
mid-sized molecules.  
 
Module Assembly Strategy 
Antibody-based drugs are one example of successful biologics, and they are currently the only 
practical PPI-directed drugs in bedside use. However, these agents have several drawbacks associated 
with their inherent large molecular size (which hampers cell penetration) and their low bioavailability 
and high cost of production. From the viewpoint of developing alternative agents that compensate for 
these drawbacks, synthetic mid-sized agents are particularly attractive as they may allow us to 
decrease the MW by more than two orders of magnitude and thus increase cell penetration and plasma 
stability. Synthesizability would also reduce the production cost. However, several questions must be 
answered for this strategy to be successful: 1) what is the most practical strategy for introducing the 
structural characteristics necessary for the surface binding of a synthetic molecule?, and 2) how can 
we reduce molecular size while retaining the binding affinity and selectivity of the agents?   
In an effort to address these questions, we began exploring a new approach for molecular design 
based on a module assembly strategy. This simple approach consists of three steps. First, the protein 
surface of interest is divided into several local regions based on structural features (e.g., cavity, charge, 
hydrophobicity, etc.). Second, relatively small organic molecules are designed as module compounds 
by introducing appropriate functional groups for complementary binding to each region. Finally, these 
modules are assembled by various means to build a multivalent mid-sized agent, which has higher 
binding affinity for large protein surfaces than does either module component alone.   
Figure 1 illustrates the concepts of several approaches for constructing PPI inhibitors, based upon 
the idea described above. We anticipated that the formation of metal complexes with ligands 
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containing various functional groups would facilitate introduction of synthetic antibody-like structural 
diversity into the agents. The resulting metal-complex libraries may be useful for identifying lead 
compounds for various protein targets (Fig. 1a). We hypothesized that target-guided synthesis would 
be a feasible approach to reduce the MW and enhance cell penetration while retaining multivalency 
for binding. The approach involves in situ synthesis of PPI inhibitors templated by targeted protein 
surfaces (Fig. 1b). Two reactive small-module compounds are designed to bind side-by-side to a 
targeted protein surface. Upon binding, the resulting proximity effect would trigger a chemical ligation, 
producing a covalently conjugated compound that is predicted to be a better PPI inhibitor than either 
module compound alone. We were also interested in exploring an approach based on bivalent 
inhibitors for the simultaneous targeting of both a cavity within and the surface of the targeted protein 
(Fig. 1c). The molecular design of such compounds can be achieved by the covalent linking of two 
modules with an appropriate spacer. The cavity-binding module should bind into the active pocket in a 
selective manner and anchor the entire molecule near the cavity, thus allowing for a minimally sized 
surface module to bind to the flat protein surface. The following sections describe the 
proof-of-concept studies based upon these hypotheses.  
 
[Insert Figure 1] 
 
Dendritic Metal Complexes for Protein Surface Recognition 
Antibody-like metal complexes featuring large surface areas and multivalency for protein surface 
recognition are attractive scaffolds for the development of PPI inhibitors as well as for metal-mediated 
protein assembly.9 We10 and others11 have been studying ruthenium(II) tris(bipyiridine) (Ru[bpy]3) 
complexes for their potential to serve as protein surface-directed agents. We first investigated a 
strategy for protein surface binding using a series of dendritic Ru(bpy)3 complexes in which crucial 
functional groups are located at different positions for recognition of the characteristic surface 
structure of α-chymotrypsin (ChT).10a The serine protease bovine pancreatic ChT (pI ~ 9) possesses a 
number of basic amino acid residues that form a characteristic ring structure around the active site. 
This positively charged surface is implicated in PPIs with naturally occurring proteinaceous 
inhibitors.12 Based on the structural characteristics of the surface of ChT, we introduced glutamic acid, 
glutamyl phenylalanine dipeptide, and two phenylalanine residues at the 4 and 4' positions of 
2,2'-bipyridine, with 5-amino isophthalic acid serving as a spacer (1–3a; Fig. 2a). The net charge of 
1–3a was fixed at –12, and the complexes ranged from 23-34 Å in diameter. A superimposition model 
suggested that 3a was of an appropriate size to cover the active site (~600 Å2) while placing the 
terminal carboxyl groups near the appropriate positively charged residues on the protein surface (Fig. 




[Insert Figure 2] 
 
The binding affinity of each complex (10 µM) to ChT was evaluated by titration, monitoring the 
change in luminescence at 620 nm in phosphate buffer at pH 7.4. Little change in luminescence was 
observed for compounds 1 and 2, but the relative luminescence strength of 3a increased upon titration 
with ChT (Fig. 2c). A simple 1:1 binding model was apparently out of line with the data, whereas a 
multiple-equilibrium model with 1:1 and 1:2 binding fit well the data set, clearly demonstrating that 
the association of 3a with ChT involves 1:1 and 1:2 (3a:ChT) complex formation, with low 
micromolar dissociation constants for each equilibrium step (Fig. 2c). Plausible models for the 1:1 and 
1:2 complexes are shown in Figure 2d. Because of the structural features of its octahedral complex, 3a 
likely possesses two binding sites composed of three isophthalic arms at each position and presumably 
forms a rod-shaped Ru(bpy)3 complex with two equivalents of ChT.  
We also evaluated the ChT inhibition activity of the Ru(bpy)3 complexes using a spectroscopic 
assay with the chromogenic substrate N-benzoyltyrosine-p-nitroanilide (BTNA). The proteinaceous 
soybean trypsin inhibitor (STI, 20 kDa) is known to bind to ChT, which implies an interfacial surface 
of 1,600 Å2, with a Kd value of 1 × 10-7 M.12 Only an equimolar amount of STI was necessary for 
complete inhibition of enzyme activity. Although compound 1 was completely inactive and 2 showed 
moderate inhibition (Fig. 3a), dendritic compound 3a showed significant inhibitory activity (74 ± 
17%), which was probably a reflection of its higher affinity for ChT compared with 1 and 2. The 
replacement of phenylalanine residues in 3a with lysine methyl esters (3b) markedly reduced the 
inhibitory activity, suggesting the possibility of electrostatic repulsion between 3b and the basic 
surface of ChT. The inactivity of the bipyridine ligand (4) is suggestive of the significance of the 
integrated effect of functional groups on protein surface binding. Based on these results, we concluded 
that 3a recognizes the protein surface through complementary interactions between carboxyl groups 
and the positively charged amino acid residues.  
In order to examine the mode of Ru(bpy)3 complex-mediated inhibition of ChT, a 
Lineweaver-Burk analysis was performed for 3a. The data set fit a noncompetitive model (Fig. 3b), 
showing that association of 3a with ChT does not interfere with binding of the substrate to the active 
site. A computationally generated model (Fig. 3c) suggested that the formation of a ternary complex 
consisting of 3a:ChT:BTNA is possible. Even when 3a binds to the targeted positively charged surface 
of ChT, enough space appears to be available for BTNA to bind to the active site. Based on this model, 
a plausible explanation for the inhibition mechanism suggests that while BTNA still binds to the active 
site, binding of 3a to the surface of ChT may induce a conformational change in the protein that 
diminishes its enzymatic activity. This may account for the relatively low inhibitory activity of 3a 
despite its submicromolar affinity for ChT. 
Heteroleptic Ru(bpy)3 complexes were also found to be potent inhibitors of cytochrome c 
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reduction and to possess a remarkable ability to penetrate cells.10b In addition, our primary results 
suggest that simple addition of ferric ion into a mixture of several bipyridine ligands containing 
various functional groups produces a dynamic combinatorial mixture of Fe(bpy)3 complexes.10c 
Screening of the complex array for inhibition of ChT and thrombin activity resulted in the 
identification of several potent mixtures for each enzyme. Work aimed at identifying the active species 
from these mixtures is underway.   
In summary, we verified that Ru(bpy)3 complexes provide a useful scaffold for the synthesis of 
protein surface-directed agents. The size of the complex, the positioning of the functional groups, and 
the complementary charge distribution were all found to have a considerable effect on the complex’s 
affinity for and inhibition of ChT.    
 
[Insert Figure 3] 
 
Target-guided Synthesis 
Reducing the molecular weight of a protein-binding agent while retaining its affinity and 
selectivity for the targeted protein surface is challenging. One strategy for addressing this problem is 
to synthesize PPI inhibitors on a targeted protein surface in situ by covalently assembling relatively 
small module compounds (Fig. 1b). The resulting agents should bind more readily to the protein 
surface than either of the module compounds alone due to the effect of additive binding energies.13 
The covalent assembly of two ligands on the surface of a protein has been exploited in a number of 
recent medicinal chemistry studies, the results of which confirm the potential relevance of this 
approach for synthesizing PPI inhibitors.14-16 In order to further evaluate the utility of the covalent 
assembly, we examined an epoxide-opening reaction between diterpene fusicoccin derivatives and a 
cysteine-containing pentapeptide, guided by the 14-3-3ζ protein, for synthesizing natural 
product-based conjugate molecules. 17  
The 14-3-3 proteins are a family of highly conserved dimeric proteins expressed in all eukaryotic 
cells. These proteins play critical roles in the regulation of serine/threonine kinase-dependent signaling 
pathways through phosphorylation-dependent binding to a large number of ligand proteins.18 Each 
14-3-3 protein monomer possesses an amphipathic groove that binds to a consensus peptide motif 
containing phosphorylated T (threonine, Thr) or S (serine, Ser) residues. Recent studies have 
implicated 14-3-3 proteins in the development of a number of diseases,19 suggesting that these 
proteins have clinical relevance as therapeutic targets.   
 
 [Insert Figure 4] 
 
The fungal phytotoxin fusicoccin A (FC-A; shown in Figure 4a in a ball-stick model with its 
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structure shown in Fig. 4b) binds to a hydrophobic cavity adjacent to the phosphopeptide-binding 
pocket of plant 14-3-3 proteins. This compound forms a stable ternary complex (Fig. 4a) with the 
phosphopeptide QSYpTV (H-Gln-Ser-Tyr-phosphoThr-Val-OH, shown in Fig. 4a in a stick model), 
which is derived from the C-terminus of plant H+-ATPase. The formation of the ternary complex is 
driven by hydrophobic interactions between the FC-A backbone and the isopropyl side chain of the V 
residue located at position i+1 relative to the pT residue. Formation of the ternary complex increases 
the affinity of both FC-A and the pentapeptide for the 14-3-3 protein by nearly two orders of 
magnitude.20 Thus, we hypothesized that reactive module compounds capable of cooperatively 
binding to the 14-3-3 groove and triggering covalent bond formation to yield the corresponding 
conjugate product could be constructed by introducing an appropriate functional group into both FC-A 
and the peptide. As a result, it should be possible to observe the 14-3-3-template effect, in which the 
ligation reaction is guided by the protein surface, resulting in enhanced conjugate production. 
To test this hypothesis, we chose an epoxide and a thiol as the reactive groups and designed 
FC-based modules and the peptide fragment accordingly (Fig. 4b). The epoxide was introduced at the 
19-position via an appropriate spacer, and the V residue in QSYpTV was replaced with a C residue to 
prepare the pentapeptide module (QSYpTC) and nonphosphorylated peptide (QSYDC). We then tested 
the reaction in the presence and absence of 14-3-3 in aqueous solution (Fig. 4c).  
We predicted that the FC-module and the C-containing peptide would bind to the 14-3-3 groove 
in a cooperative manner (Fig. 5a), which would trigger the reaction between the epoxide and the thiol 
group to form the corresponding conjugate product (Fig. 5b). In order to confirm the cooperative 
binding of the FC-module and the peptide module to 14-3-3, the binding affinity of QSYpTC for 
recombinant 14-3-3ζ in the presence and absence of nonreactive compound 10 was compared using 
isothermal titration calorimetry (Fig. 6a). The binding affinity increased by approximately one order of 
magnitude in the presence of 5 equivalents of 10 (Kd = 0.41 and 0.046 µM in the absence and presence, 
respectively, of 10), suggesting that the FC derivatives retained the ability to stabilize the interaction 
between 14-3-3 and the peptide.  
 
 [Insert Figure 5] 
 
The template effect of 14-3-3 upon conjugate formation was then evaluated using HPLC. The 
FC-based modules (7-9, 300 µM) were incubated with QSYDC (300 µM) in Tris-HCl buffer (pH 9.0) 
in the presence and absence of 14-3-3ζ (300 µM). The percentage of each conjugate generated ([+] 
14-3-3/[−] 14-3-3 × 100) was calculated based on relative yield (Fig. 6b). In the case of 6, in which the 
epoxide group was directly attached to the C-19 of FC, 14-3-3 reduced conjugate production to 37% 
of the control, suggesting that although 6 and QSYDC bound to the 14-3-3 groove, the epoxide did not 
reach the thiol group in QSYDC, presumably due to restriction imposed by rotation of the amide bond. 
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In contrast, formation of conjugate in the reaction involving 7 was enhanced by 14-3-3 (199% of the 
control), demonstrating the template effect of 14-3-3. Compounds 8 and 9, which contain longer 
spacers than 7, reduced the efficiency of conjugate formation (169 and 129% of the control, 
respectively), suggesting that appropriate positioning of the epoxide is a key factor in the templated 
reaction. 
 
 [Insert Figure 6] 
 
In summary, the template effect of the 14-3-3 protein on the chemical ligation of fusicoccin 
derivatives containing an epoxide group and the pentapeptide QSYDC was confirmed. These results 
support the potential application of 14-3-3–guided chemical ligation for in situ generation of PPI 
inhibitors.  
 
Bivalent Enzyme Inhibitors 
a) Module design for inhibitors that simultaneously recognize the active site and surface of Type 
I geranylgeranyltrasferase (GGTase-I) 
Synthetic chemical probes designed as part of a new concept for simultaneously targeting 
multiple sites on a protein’s surface are of interest due to their potential application as site-specific 
modulators of PPIs. In this section, we discuss a new approach for synthesizing bivalent inhibitors of 
mammalian type-I geranylgeranyltransferase (GGTase-I) based on the assembly of modules for 
simultaneous recognition of both the active site and the protein surface (Fig. 1c).   
GGTase-I21 is a heterodimeric zinc-containing metalloenzyme and a member of the protein 
prenyltransferase family. Mammalian GGTase-I is responsible for transferring a C-20 geranylgeranyl 
group from geranylgeranyl pyrophosphate (GGPP) to a C residue of the carboxy-terminal CAAX 
tetrapeptide of the target substrate protein, in which AA is an aliphatic dipeptide, and, in most cases, X 
is a L or F residue. 22,23 GGTase-I has garnered considerable attention due to its potential as a new drug 
target for treatment of cancer24 and other diseases, such as smooth muscle hyperplasia25 and hepatitis 
C.26  
 
[Insert Figure 7] 
 
Mammalian GGTase-I consists of a 48 kDa α-subunit and a 43 kDa β-subunit that contains the 
hydrophobic active pocket. Crystal structures of the ternary complex of GGTase-I bound to the peptide 
and a GGPP analog revealed that there is a characteristic acidic region on the surface of the α-subunit 
near the entrance to the active pocket.27 We therefore applied the concept of designing bivalent 
inhibitors to simultaneously target both the active site and the acidic surface of GGTase-I (Fig. 7a). 
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The active-pocket module should bind in the cavity in a selective manner and should anchor the entire 
molecule near the pocket, whereas the surface-binding module requires relatively divergent structural 
features and multiple positively charged groups for the electrostatic interaction with the GGTase-I 
surface. The inhibitors synthesized in this study consisted of two modules linked by an alkyl spacer; 
one was the tetrapeptide CVIL module for binding to the active pocket, whereas the other was a 
3,4,5-alkoxy substituted benzoyl motif containing three aminoalkyl groups designed to bind to the 
negatively charged protein surface near the active site (Fig. 7b).  
The compounds were screened for inhibition of GGTase-I activity using an enzyme inhibition 
assay based on fluorescence spectroscopy.  Briefly, recombinant GGTase-I was treated with 
compound in the presence of geranylgeranyl pyrophosphate (GGPP, 5.0 µM) and the environmentally 
sensitive fluorogenic substrate, N-dansyl-GCVIL (DansGCVIL; 1.0 µM) in Tris-HCl buffer (50 mM, 
pH 7.5).  This substrate increases the fluorescent intensity upon geranylgeranylation at the cysteine 
thiol group.  The fluorescent increase was monitored for 5 min and the percentage of inhibition was 
calculated by comparison with the standard slope, which was taken from the reaction in the absence of 
inhibitors. The bivalent inhibitors effectively blocked GGTase-I activity, and their potency was found 
to be approximately one order of magnitude and >150 times more effective than the tetrapeptide CVIL 
and methyl benzoate derivatives, respectively, confirming the synergistic effect on enzyme inhibition 
(Fig. 8a). A comparison of the effects of compounds 11-13 demonstrated that the spacer length affects 
the inhibitory activity (Fig. 8b). Compound 13 (n = 3; “n” refers to the number of carbons in the 
spacer), which contains a shorter spacer for the C2 unit than does compound 12 (n = 5, Ki = 0.22 ± 
0.04 µM), was a slightly less active inhibitor than 12 (for 13, Ki = 0.48 ± 0.11 µM). On the other hand, 
compound 11 (n = 11), with a spacer length twice as long as that of 12, dramatically lost its inhibition 
potency (Fig. 8b). This suggests that longer spacers diminish the affinity of binding to GGTase-I due 
to entropic disadvantage28 and that the length of the spacer for module assembly should be carefully 
chosen to achieve optimal activity.  
 
[Insert Figure 8] 
 
Kinetic analyses revealed that the bivalent compounds are competitive inhibitors (Fig. 8c), 
suggesting that the CVIL module anchors the entire molecule to the active site and delivers the other 
module to the targeted protein surface. Thus, our module assembly approach provides for 
simultaneous recognition of multiple sites and consequent synergistic inhibition of GGTase-I activity, 
thereby providing a new approach for designing protein surface-directed PPI inhibitors.  
 
b) Bivalent dual inhibitors that disrupt PPIs of K-Ras and protein prenyltransferases 
Next, we examined the critical question of whether bivalent inhibitors are useful for disrupting 
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PPIs. To address this question, we focused on posttranslational modification of the K-Ras-4B protein, 
which is normally regulated by farnesyltransferase (FTase).   
 
[Insert Figure 9] 
 
The heterodimeric zinc metalloenzyme FTase is structurally and functionally similar to GGTase-I 
(Fig. 9). Importantly, the 48 kDa α-subunits of both proteins are identical and are products of the same 
gene. Thus, both FTase and GGTase-I possess a negatively charged area in which a number of acidic 
amino acids are clustered.29 Over the last two decades, these two enzymes have received intense 
attention as potential clinical targets.30 Furthermore, a recent genetic study suggested that dual 
inhibitors of both enzymes would be promising cancer therapeutic agents.31  
Human K-Ras4B is the most frequently mutated Ras isoform in cancers. This protein is normally 
farnesylated by FTase at the thiol group of the C-terminal CVIM sequence (Fig. 10, solid arrows). 
However, disruption of K-Ras4B farnesylation by FTase inhibitors causes an alternative 
geranylgeranylation by GGTase-I (Fig. 10, dashed arrows), which enables K-Ras4B to retain full 
biological activity.32 Biological studies29,33 have demonstrated that a critical determinant for the 
unusual geranylgeranylation of K-Ras4B is the characteristic polylysine sequence near the protein’s 
C-terminus. This highly positively charged region is believed to trigger a transient PPI with the acidic 
surfaces of FTase and GGTase-I through electrostatic interactions. Thus, we predicted that a 
compound mimicking the C-terminal structure of K-Ras4B would simultaneously bind to the active 
site and the acidic surface of both FTase and GGTase-I and block the transient PPI, resulting in dual 
inhibition of the farnesylation and geranylgeranylation of K-Ras4B. 
 
[Insert Figure 10] 
 
To test this hypothesis and to evaluate the disruption of the PPI between K-Ras4B and FTase and 
GGTase-I, we first set up a modified in vitro assay system using a dansylated oligopeptide truncated 
from the K-Ras-4B C-terminal sequence (KKKKKKSK(Dans)TKCVIM, Fig. 11). We then designed 
the bivalent compounds based on the C-terminal structural features of K-Ras4B. For designing the 
active-site module, we employed a strategy similar to that described in the previous section for design 
of the GGTase-I inhibitors. Namely, we initially chose the CVIM tetrapeptide to ensure that the 
module would bind to the FTase active site. To mimic the (K)6 region, we used a gallate scaffold in 
which the same number of primary amino groups were introduced using branched alkyl amines. Two 
modules were covalently linked via an alkyl spacer to produce compound 15. We anticipated that 
compound 15 would suppress the farnesylation of the K-Ras4B model peptide much more effectively 
than CVIM alone, as 15 features the additional module that disrupts the interaction between the acidic 
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surface of FTase and the positively charged area of the model peptide, a module which CVIM does not 
contain. 
 
[Insert Figure 11] 
 
As shown in Figure 12a, 15 exhibited remarkable inhibition of FTase activity (Ki = 0.005 µM) 
and was >200 times more effective than CVIM (Ki = 1.10 µM).34 In addition, a Lineweaver-Burk 
analysis shows that the mode of inhibition by 15 is competitive.34 These results clearly indicate that 
the compound binds to the active site, delivers the minimally sized surface module to the acidic 
protein surface, and disrupts the interaction between the substrate and the protein surface.  
We then tested 15 for inhibition of the geranylgeranylation of the K-Ras4B model peptide (Fig. 
12a). Alone, CVIM inhibited GGTase-I activity only moderately (Ki = 6.69 µM), which is not 
surprising because CVIM is not the sequence that is preferably recognized by the GGTase-I active 
pocket. In contrast, compound 15 significantly suppressed geranylgeranylation of the model peptide 
(Ki = 0.344 µM), demonstrating that by attaching the gallate module, the ineffective CVIM peptide is 
converted into a reasonably effective GGTase-I inhibitor.  
We also evaluated FTase inhibition using structure-activity relationship analysis (Fig. 12b). 
Whereas replacement of the alkyl spacer in 15 by an ethylene glycol chain had only a minimal effect, 
reducing the number of amino groups in the gallate module by half diminished the activity (as seen 
with compound 17). Furthermore, replacement of the amino groups in 17 with carboxylate groups 
dramatically reduced the activity, confirming that the gallate module is involved in the electrostatic 
interaction with the acidic surface of FTase. Most importantly, only the gallate module was found to 
be completely inactive, even at high concentrations (>100 µM). This confirms that it is the anchoring 
effect provided by the CVIM module that enables this small and weak surface module to both disrupt 
PPIs and function as a dual inhibitor of FTase and GGTase-I activity.   
 
[Insert Figure 12] 
 
To improve the cell-based activity of the bivalent dual inhibitors, we tested the effect of 
peptidomimetic modification of the CVIM module.35 Fluorescence imaging analysis revealed that 
introducing a peptidomimetic FTI-24936 for the active site module (as seen in compound 19, Fig. 13) 
enhanced cell penetration. A cell-based evaluation demonstrated that peptidomimetic 19 at a 
concentration of 100 µM inhibited HDJ-2 (a human 40 kDa heat shock protein) processing in cells, 
indicating that this peptidomimetic modification improves cell penetration, thus enhancing the 
whole-cell activity of the bivalent compounds.35a Further modification of the surface module by 
replacement of amino groups with guanydyl groups also improved cell-based activity, resulting in a 
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compound exhibiting submicromolar activity in cells.35b Further evaluation of the intracellular dual 
inhibition activity of this compound is underway in our laboratory.  
 
[Insert Figure 13] 
 
In summary, we used a module assembly approach to design bivalent enzyme inhibitors by 
covalently linking the active-pocket and surface modules with an appropriate spacer. The resulting 
compounds significantly inhibited model transient PPIs. Peptidomimetic modification improved the 
whole-cell activity of the compounds. The anchoring strategy discussed here may lead to a general 
approach for designing selective and cell-penetrating mid-sized PPI inhibitors as well as dual enzyme 
inhibitors targeting exterior protein surfaces.  
 
Conclusions 
Based on the simple concept of modular assembly of mid-sized molecules, we studied several 
methodologies for constructing multivalent agents that are capable of binding to protein surfaces. Our 
results from the study of Ru(bpy)3 support the potential application of transition metal complexes for 
further development of PPI inhibitors. These structurally tuneable scaffolds may serve as useful tools 
in structure-activity relationship investigations of protein surface-directed agents. The moderate 
inhibitory activity of homoleptic Ru(bpy)3 against ChT needs to be improved. Dynamic combinatorial 
libraries containing homo- and heteroleptic metal complexes may be beneficial in searches for the best 
combination of ligands necessary for specific interaction with targeted protein surfaces.   
Although target-guided inhibitor synthesis is a challenging approach for the development of PPI 
inhibitors, our initial studies involving 14-3-3 suggest that module-conjugate synthesis templated by a 
target protein can be achieved. Of course, critical issues remain to be resolved, for instance, improving 
the reaction efficiency and inhibition potency of the resulting conjugate and determining how to 
overcome diffusion problems. These questions will need to be addressed during further development 
of the strategy.   
Our results prove that designing bivalent enzyme inhibitors is a promising strategy that allows for 
1) exploiting minimally sized surface modules that are weak binders by themselves, 2) disrupting 
transient PPIs, and 3) dual inhibition of enzymes such as FTase and GGTase-I. We expect that this 
methodology will be applicable to the inhibition of other PPIs if the targeted proteins possess cavities 
or an active pocket. In addition, the concept of simultaneous binding to both the active site and protein 
surface may lead to a general strategy for designing dual enzyme inhibitors targeting common or 
similar protein surface structures in addition to the traditionally targeted active pockets. Development 
of synthetic inhibitors of PPIs will certainly require more work to assess their relevance and feasibility. 
However, we believe that focusing on mid-sized molecules will help us to move toward a new 
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paradigm and define the pharmacological properties that are necessary for a synthetic compound to be 
a potential drug for this class of targets.  
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In an effort to explore new methodologies that are applicable to the design of synthetic inhibitors of 
protein-protein interactions, we examined a strategy based on the assembly of small module 
compounds to create multivalent mid-sized agents. Three particular approaches for assembling 
modules, metal-chelating, covalent chemical ligation templated by a targeted protein, and bivalent 
inhibitor design for simultaneous targeting of the cavity and surface, are described. These strategies 
were shown to be useful for synthesizing minimally sized synthetic agents for targeting PPIs and may 












Fig. 2. (a) Structure of Ru(bpy)3 complexes 1-3. (b) A superimposed model of 3a (CPK) and ChT. (c) 
Titration curves for 10 µM 1, 2, and 3a. (d) A plausible model for 1:1 and 1:2 binding of 3a (CPK) to 






Fig. 3. (a) Inhibition of ChT by Ru(bpy)3 complexes 1-3 and ligand 4 (75 µM). Inhibition assays were 
performed using N-benzoyltyrosine-p-nitroanilide (BNTA, 100 µM). (b) Kinetic analysis of the 
inhibition of ChT by 3a (0 (●), 10 (○), and 30 (▼) µM). (c) A plausible model for the ternary complex 






Fig. 4. (a) Crystal structure of the ternary complex of 14-3-3, fusicoccin A (FC-A) (ball and stick), and 
the phosphopeptide QSYpTV (stick). PDB ID = 1of9. (b) Chemical structure of FC-A and FC-based 




Fig. 5. Hypothetical model of epoxide-containing fusicoccin (5: white stick) and pentapeptide 
fragment QSYpTC (gray stick) bound to 14-3-3. (a) Compound 5 and QSYpTC bind to the 14-3-3 





Fig. 6. (a) Isothermal titration calorimetry measurements. Left: experiment in which QSYpTC was 
titrated in 14-3-3ζ (40 µM). Right: titration of QSYpTC in 14-3-3 ζ (40 µM) in the presence of 
compound 10 (200 µM). (b) Relative yield of conjugates generated by the ligation reaction between 
compounds 6-9 (300 µM) and the QSYDC pentapeptide (300 µM) in the presence and absence of 
14-3-3ζ (300 µM). The percentage of each conjugate product ([product, +14-3-3]/[product, –14-3-3] × 





Fig. 7. (a) Schematic representation of the module design of bivalent GGTase-I inhibitors. (b) A 




Fig. 8. (a) Dose-response curves for the modules CVIL, gallate derivative, spacer-attached CVIL, and 
compound 14 plotted against percent inhibition of GGTase-I activity. (b) Dose-response curves for the 
bivalent compounds with variable-length spacers (11-13). (c) Kinetic analysis of the inhibition of 





Fig. 9. Crystal structures of the ternary complexes of mammalian FTase (1D8D) and GGTase I 
(1N4Q) bound to the peptide substrate and prenyldiphosphate analogs. The acidic areas of the 




Fig. 10. Schematic representation of the prenylation pathways of K-Ras-4B proteins: normal 
farnesylation (solid arrows) and unusual geranylgeranylation (dashed arrows) mediated by FTase and 











Fig. 12. (a) Dose-response curves for the inhibition of FTase and GGTase-I activity by the peptide 
CVIM and compound 15. (b) IC50 values (µM) for inhibition of FTase activity. Fluorescent in vitro 
assays were carried out using DansGCVIS (1 µM) and FPP (5 µM) in 50 mM Tris-HCl buffer (pH 






Fig. 13. Chemical structure of peptidomimetically modified bivalent compound 19.  
 
